Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants. Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant,
Biotechnology, Pharmaceuticals, Health
2026-07-22 4:50 PM EDT | Hemostemix Inc.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Binding Letter of Intent to Acquire Evergreen Pharmacy; Expected to Add Over US$78 Million in Annual Revenue
Custom Health has entered into a binding letter of intent (the "LOI") to acquire Evergreen Pharmacy LLC ("Evergreen"), a Wisconsin-based specialty pharmacy specializing in the management of complex therapies for chronic disease states. Evergreen generated Revenue of approximately US$78.8 million with Normalized EBITDA (1) of US$0.60 million, for the twelve-month period ended December 31, 2025. Evergreen is a profitable company on both EBITDA an
Technology, Pharmaceuticals, Health
2026-07-22 6:30 AM EDT | Custom Health Holdings Inc.
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise Tor
Biotechnology, Pharmaceuticals
2026-07-21 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the sig
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-07-21 12:40 AM EDT | Bachem Holding AG
Richards Group Inc. Announces July 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended July 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on July 31, 2026 and will be payable on August 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-07-20 3:54 PM EDT | Richards Group Inc.
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science. CBIH's invention centers on an intranasal me
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-07-20 7:00 AM EDT | Cannabis Bioscience International Holdings
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Red Cloud Securities Inc. ("Red Cloud"), subject to all required regulatory approvals, including the approval of the TSX Venture Exchange (the "TSXV") to provide market stabilization a
Pharmaceuticals, Mining and Metals
2026-07-17 5:30 PM EDT | Voyageur Pharmaceuticals Ltd.
HarmonyRx Highlights 22 Years of Pharmacy Benefits Expertise, Building on Foundation as Broadreach Medical Research (BMR)
New York, New York--(Newsfile Corp. - July 15, 2026) - Since its founding as Broadreach Medical Research (BMR) in 2004, HarmonyRx has remained committed to transparency, clinical expertise and helping employers optimize pharmacy benefits. With more than two decades of experience in pharmacy benefits, HarmonyRx has grown alongside a rapidly changing healthcare landscape. As pharmacy costs have increased and benefit models have become more complex, the organization has remained focused on
2026-07-15 8:15 AM EDT | HarmonyRx
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics. PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printi
Biotechnology, Pharmaceuticals
2026-07-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Extendicare Announces July 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - July 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of July 2026, which is payable on August 17, 2026 to shareholders of record at the close of business on July 31, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare
Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-15 8:00 AM EDT | Extendicare Inc.
BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHar
Biotechnology, Pharmaceuticals, Health
2026-07-15 7:30 AM EDT | BioHarvest Sciences Inc.
Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products
Houston, Texas--(Newsfile Corp. - July 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that the State of Texas has approved the Company's license to manufacture and distribute consumable hemp products. This approval turns years of vision, science, and preparation into action and marks the moment CBIH steps into the market and begins commercial distribution. The Company e
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-07-15 7:00 AM EDT | Cannabis Bioscience International Holdings
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the protection of its proprietary innovations across key international markets. The company has received multiple favorable patent actions encompassing three
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-15 7:00 AM EDT | Phio Pharmaceuticals Corp.
Telescope Announces Changes to its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of intelligent automation and advanced chemical manufacturing technologies, announces that Ali Pejman has resigned from the Company's Board of Directors ("Board"), effective as of the date of this press release. Henry Dubina, CEO, stated, "On behalf of the Board and management, I would li
Technology, Chemical, Pharmaceuticals
2026-07-14 7:32 PM EDT | Telescope Innovations Corp.
Nextleaf Evolves Glacial Gold, Building Trust with Wellness Consumers
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the evolution of Glacial Gold, the Company's flagship consumer cannabis brand. The most significant evolution in Glacial Gold's history, a milestone that reflects Nextleaf's continued development into a consumer-packaged goods ("CPG") comp
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-07-13 9:29 AM EDT | Nextleaf Solutions Ltd.
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor me
2026-07-13 8:00 AM EDT | BetterLife Pharma Inc.
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.
Biotechnology, Pharmaceuticals, Health
2026-07-13 8:00 AM EDT | BioHarvest Sciences Inc.